The market gyrations and the shutdown. The trade wars and global uncertainty. None of the above has squashed the sunny optimism that a group of healthcare CEOs demonstrated at a roundtable discussion during the annual J.P. Morgan Healthcare Conference in San Francisco last week.
Private, Dublin-based biotech United Neuroscience says it plans to rapidly advance its active Alzheimer’s vaccine immunotherapy UB-311 after reporting positive top-line results from a Phase IIa study of 42 patients on Jan. 16. The company’s lead candidate UB-311 is a novel synthetic peptide that targets beta amyloid in Alzheimer’s disease, with the goal of preventing and treating […]
United Neuroscience Ltd. posted top-line results from a phase IIa study of UB-311, its synthetic peptide vaccine candidate targeting beta-amyloid (A-beta) for the treatment of Alzheimer’s disease (AD), showing the effort met the primary aims of safety and immunogenicity with a 96 percent response rate. Secondary endpoints, which included amyloid PET burden as well as scores from […]